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Loss- and gain-of-function transgenic models are
powerful tools for understanding gene function
in vivo but are limited in their ability to determine
relative protein requirements. To determine cell-
specific, temporal, or dose requirements of complex
pathways, new methodology is needed. This is
particularly important for deconstructing metabolic
pathways that are highly interdependent and cross-
regulated. We have combined mouse conditional
transgenics and synthetic posttranslational protein
stabilization to produce a broadly applicable strategy
to regulate protein and pathway function in a cell-
autonomous manner in vivo. Here, we show how a
targeted chemical-genetic strategy can be used to
alter fatty acid metabolism in a reombination and
small-molecule-dependent manner in live behaving
transgenic mice. This provides a practical, specific,
and reversible means of manipulating metabolic
pathways in adult mice to provide biological insight.
INTRODUCTION
Metabolic pathways are highly interconnected and interdepen-
dent. They also exhibit remarkable plasticity that can be easily
mistaken for or complemented by redundancy. Understanding
these complexities requires specific temporal and reversible
pathway perturbation. This is often done using rather non-
specific pharmacology. Ideally, one could use small molecules
to selectively and potently alter enzyme activity in an allele-
specific manner by means that would require little knowledge
of the reaction mechanism. The technique would therefore be
straightforward and broadly applicable and would occur
posttranslationally.
There is great interest in the development of small molecules
that regulate the function of user-engineered proteins (Bishop
et al., 2000; Haruki et al., 2008; Matsuzawa et al., 2005; McGin-
ness et al., 2006; Robinson et al., 2010), particularly in the
context of intact organisms (Chen et al., 2005; Karpova et al.,
2005; Liu et al., 2007; Stankunas et al., 2003). Recently, there
has been considerable progress in the development of small
stabilizing or destabilizing protein domains that interact with
well-defined inert small molecules (Banaszynski et al., 2006,
2008; Bonger et al., 2011; Iwamoto et al., 2010; Kanke et al.,Chemistry & Biology 19, 32011; Nishimura et al., 2009). Natural or synthetic small-mole-
cule ligands are chosen that interact with specific proteins
to either promote or inhibit their rapid posttranslational degrada-
tion (Janse et al., 2004). Fusion of a protein of interest to these
domains creates a small-molecule-regulated protein whose
function is dose-dependent and reversible. Here, we have
combined ligand-inducible protein stabilization with genetically
tractable recombination-mediated transgene expression to
enable the targeted small-molecule regulation of enzyme activity
in live mice.
In order to utilize this strategy to study metabolites in vivo, we
developed a transgenic vector that allows the small-molecule
regulation of malonyl-CoA decarboxylase (MLYCD) after Cre-
mediated recombination. MLYCD was chosen because its
substrate, malonyl-CoA, represents a central metabolic node
in fatty acid biochemistry. Malonyl-CoA is the product of the
rate-setting step in de novo fatty acid metabolism, is the
substrate for fatty acid synthesis and elongation, and allosteri-
cally inhibits the rate-setting step in fatty acid beta-oxidation
(Wolfgang and Lane, 2006). Therefore, exerting control over
malonyl-CoA through MLYCD has broad experimental utility.
This approach is not limited to MLYCD but is broadly applicable
to other enzymes and genes.
RESULTS
Design of a Small-Molecule-Regulated Malonyl-CoA
Decarboxylase
In order to produce dose-dependent, small-molecule-regulated
posttranslational stabilization, Wandless et al. constructed
a modified FK506 binding protein 12 (FKBP12) that binds to
and is reversibly stabilized by a synthetic, biologically inert small
molecule, Shield-1 (Banaszynski et al., 2006, 2008; Maynard-
Smith et al., 2007). We made several modifications to the
FKBP12-based destabilization vectors. A picornavirus PTV1-
2A peptide-linked mCherry was fused in-frame after an FKBP-
eYFP destabilization fusion protein and then cloned into an
MMLV-based selectable retroviral vector (Figure 1A). The 2A
peptide allows two proteins to be produced from a single
mRNA at a 1:1 stoichiometric ratio, enabling a ratiometric, auton-
omous measurement of stabilization and localization within
cells (Provost et al., 2007; Szymczak et al., 2004). Malonyl-CoA
decarboxylase (MLYCD) was then cloned as a C-terminal fusion
with FKBP-YFP flanked by two short flexible linkers. Fusion of
the mutant FKBP12 to YFP linked to MLYCD allows real-time
visualization of Shield-1-induced stabilization. The N-terminal
mitochondrial localization domain and C-terminal peroxisomal91–398, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 391
Figure 1. Small-Molecule-Induced Enzyme Stabilization
(A) An FKBP12 destabilization domain that is inducibly stabilized by the small molecule Shield-1 was fused to eYFP and malonyl-CoA decarboxylase (MLYCD).
The inducible MLYCE is linked to a constitutively expressed mCherry via a bicistronic viral PTV1-2A peptide.
(B) Epifluorescent images of Shield-1-stabilized MLYCD and constitutive expression of mCherry in HEK293T cells.
(C and D) Western blots of dose-dependent Shield-1-induced stabilization of control (C) and MLYCD (D) HEK293T cells.
(E and F) Time course (E) and washout (F) of stabilization in HEK293T cells.
Figure 2. Shield-1-Regulated Malonyl-CoA Decarboxylase Activity
(A) Shield-1 induces MLYCD activity.
(B) Shield-1 suppresses de novo fatty acid synthesis in a dose-dependent
manner as measured by 3H-acetate incorporation into lipids.
Error bars represent the SEM.
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cytoplasmic MLYCD activity (An et al., 2004). Two stable
HEK293T stable cell lines were produced that express
FKBP12-eYFP-MLYCD-2a-mCherry (FY-MLYCD) or FKBP12-
eYFP-2a-mCherry (FYFP) to conduct an initial characterization
of this system in vitro. Shield-1 was synthesized as previously
reported (Banaszynski et al., 2006; Yang et al., 2000).
In order to verify that the stable cells expressed mCherry
constitutively and eYFP in a Shield-1-dependent manner
(Figures 1A–1D), stable cell lines were treated with Shield-1 for
16 hr. Addition of Shield-1 induced FYFP and FY-MLYCD in
a dose-dependent manner (Figures 1C and 1D). To determine
the kinetics of stabilization, stable cells were incubated with
Shield-1 and collected at the designated time points. Saturation
of stability was achieved 12 hr posttreatment (Figure 1E). Like-
wise, we conducted a washout experiment to determine the
kinetics of destabilization. Stable cells returned to basal stabili-
zation levels 48 hr after Shield-1 removal (Figure 1F). These
data show that Shield-1 induced MLYCD stabilization in
a dose-dependent and reversible manner.
To demonstrate that the FY-MLYCD fusion protein was enzy-
matically active, we treated FY-MLYCD stable cells with Shield-1
or vehicle control for 16 hr. Indeed, Shield-1 induced an 4-fold
increase in MLYCD activity (Figure 2A). In a second experiment,
increasing amounts of Shield-1 were added to FY-MLYCD cells
and then the cells were assayed for 3H-acetate incorporation into
lipids, a measure of de novo fatty acid synthesis. Addition of
Shield-1 resulted in a dose-dependent suppression of de novo
fatty acid synthesis, demonstrating that FY-MLYCD was enzy-392 Chemistry & Biology 19, 391–398, March 23, 2012 ª2012 Elseviematically active and its activity was regulated by Shield-1 in
a dose-dependent manner (Figure 2B). These experiments
show that the fusion of the mutant FKBP12 to MLYCD main-
tained an active enzyme that can be regulated by Shield-1.
Dual Chemical and Genetic Regulation of Fatty Acid
Metabolism In Vivo
Shield-1 has been shown previously to be active when injected
into mice, either intravenously or intraperitoneally, in a tumor
xenograft model to regulate secreted fusion proteins in vivor Ltd All rights reserved
Figure 3. Dual Chemical Regulation of Protein Stability
(A) The destabilization cassette was cloned downstream of a Lox2272 eCFPcaax Stop cassette driven by the ubiquitous CMV-enhanced chicken beta actin
promoter (CAG). Cre-mediated recombination between the Lox sites excises the eCFPcaax Stop cassette and expresses the FKBP12-YFP-MLYCD-2A-mCherry
cassette.
(B) Differential eCFP tissue expression in transgenic mice as shown by Western blot.
(C) Western blot of MEFs from double-conditional Tg-fMCDERT2 mice. Isolated MEFs were treated with 500 nM 4-hydroxytamoxifen (4HT) and Shield-1 or vehicle
control and blotted for FKBP12 (stabilization), mCherry (recombination), and HSC 70 (loading control).
(D and E) Time course (D) and washout (E) stabilization of MLYCD.
(F) Epifluorescent images of tamoxifen-inducible Shield-1-stabilized primary MEFs.
Chemistry & Biology
Targeted Chemical-Genetics(Banaszynski et al., 2008). Given the success of Shield-1 in mice,
we proceeded to modify this technology into a genetically trac-
table and targeted in vivo mammalian expression system
to affect metabolism in live behaving mice. The vector was
designed to enable the conditional targeted expression of
a Shield-1-regulated cassette in transgenic mice. A lox2272-
flanked eCFPcaax stop cassette was cloned into a ubiquitous
mammalian expression vector (Reamy and Wolfgang, 2011).
Lox2272 was chosen because it does not recombine with tradi-Chemistry & Biology 19, 3tional loxP sequences used in most conditional knockout (KO)
mice (Araki et al., 2002). The FY-MLYCD transgene was cloned
downstream of the floxed stop cassette (Figure 3A). FY-MLYCD
is produced only after Cre-mediated excision of the eCFP stop
cassette. Transgenic mice expressing Lox2272-eCFPcaax pA
Lox2272-FKBP12-eYFP-MLYCD-2a-mCherry (Tg-fMCD) were
produced and characterized for eCFP expression by Western
blot and direct epifluorescent visualization in cryosections.
CFP expression was the highest in the muscle, pancreas, and91–398, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 393
Figure 4. Chemical Genetic Regulation of MLYCD In Vivo
(A) Fluorescent confocal images of Shield-1 stabilization in the pancreas of
conditionally regulated Tg-fMCDERT2 mice. Animals were injected with
tamoxifen (200 mg/kg), followed by Shield-1 (10 mg/kg) or vehicle control.
(B) Western blots of FY-MLYCD stabilization by Shield-1 in the pancreas,
skeletal muscle, heart, and adipose tissue of Tg-fMCDERT2 mice.
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These mice were then crossed to mice that ubiquitously express
a tamoxifen-inducible Cre recombinase, CREERT2 (Ruzankina
et al., 2007) to produce double-transgenic mice (Tg-fMCDERT2)
in order to initially characterize the Shield-1-inducible system
in multiple tissues. These Shield-1-regulated transgenic mice
can be bred to any transgenic Cre-recombinase-expressing
mouse to achieve tissue specificity or temporal regulation with
inducible Cre mice, or both. The flexibility of having dual induc-
ible systems is particularly beneficial in cases where the induc-
tion of genes is desired in both a cell-specific and temporal
manner. This transgenic vector can be easily tailored to meet
individual needs.
Primary mouse embryonic fibroblasts (MEFs) were derived
from double-transgenic mice. The MEFs exhibited membranous
eCFP expression as a marker for transgene expression. The
addition of 4-hydroxy-tamoxifen resulted in recombination and
expression of mCherry (marker for recombination), but not of
FY-MLYCD (Figures 3C and 3F). Addition of Shield-1 resulted
in the expression of cytoplasmic FY-MLYCD (Figure 3F) in
a dose-dependent manner (Figure 3C). We conducted kinetic
studies to determine the stabilization of FY-MLYCD after
4-hydroxy-tamoxifen and Shield-1 addition. Peak stabilization394 Chemistry & Biology 19, 391–398, March 23, 2012 ª2012 Elseviewas reached at 24 hr (Figure 3D), while washout studies showed
that MEFs returned to basal stabilization levels 96 hr after
Shield-1 removal (Figure 3E). These results demonstrate that
MLYCD is dually regulated by Cre-mediated recombination
and Shield-1 ex vivo.
Next, we tested this dual regulatory system in vivo. Tg-
fMCDERT2 animals were injected four times with 200mg/kg intra-
peritoneal (i.p.) tamoxifen over 1 week to induce recombination
of the eCFPcaax domain in vivo. After a 48 hr rest period, mice
received three i.p. injections of Shield-1 at 10 mg/kg at 12 hr
intervals. Transgene expression was assessed by the expres-
sion of membranous eCFP (Figure 4A). Recombination was
seen in vivo as the expression of untargeted mCherry. Stabiliza-
tion was visualized by the expression of cytoplasmic eYFP. Little
to no expression of eYFP can be seen in the absence of Shield-1
(Figure 4A). Destabilization occurs robustly in vivo, as almost no
expression was seen in the absence of Shield-1. mCherry and
eYFP expression fully overlapped. No cells were observed ex-
pressing eYFP in the absence of mCherry expression. Shield-1
stabilized FY-MLYCD in tissues that express the transgene,
including the pancreas, skeletal muscle, heart, and adipose
tissue (Figures 4B–4E). The Tg-fMCDERT2 mice exhibited dual
regulation of FY-MLYCD in multiple tissues.
Finally, we tested the ability of Tg-fMCDERT2 mice to alter the
oxidation of fatty acids in livemice. Two genotypeswere chosen,
Tg-fMCDERT2 and control Tg-fMCDmice. Tamoxifen was admin-
istered to all mice as described above to mediate recombination
and expression of the FYMLYCD transgene in Tg-fMCDERT2
mice. Mice were then given either Shield-1 or vehicle as above.
The mice were then assayed individually for their ability to fully
oxidize radiolabeled palmitate to CO2. Shield-1 had no effect
on control mice, however, Shield-1 induced an 3-fold increase
in fatty acid oxidation in the fed state (Figure 5). This is approxi-
mately the increase in fatty acid oxidation seen during prolonged
fasting (Wolfgang et al., 2006). Here, we were able to achieve
robust changes in themetabolism of fatty acids in livemice using
an inert small molecule while simultaneously using wild-type
littermates to control for any potential off-target effects of the
chemical. These experiments provide the proof of principle for
a broadly applicable means to alter protein and metabolic func-
tion in vivo.
Tissue-Specific and Dose-Dependent Small-Molecule
Regulation of Malonyl-CoA Decarboxylase In Vivo
The ubiquitous tamoxifen-inducible Cre-recombinase-express-
ing mouse used above has the advantage of temporal (chemical)
and ubiquitous control of recombination. Thesemice were useful
for monitoring basic pharmacodynamics of stabilization in
multiple tissues, as well as permitting mosaic recombination to
serve as an additional internal cell-autonomous control (Fig-
ure 4A). This approach is not ideal, however, for dissecting
tissue-specific effects of metabolic pathways in the context of
whole-animal physiology. To test this system in a tissue-specific
context, we crossed our transgenic mice (Tg-fMCD) to mice
expressing Cre recombinase from the human alpha-skeletal
muscle actin promoter (Miniou et al., 1999) (Tg-fMCDskel). The
expression of the muscle-specific Cre recombinase resulted in
the deletion of eCFPcaax in muscle without deletion in nonpar-
enchymal tissue, as expected (Figure 6A). This strategy resultedr Ltd All rights reserved
Figure 5. Chemical-Genetic Regulation of Fatty Acid Metabolism
In Vivo
Live mouse in vivo oxidation of 1-14C labeled palmitic acid to 14CO2 for 45min.
n = 3/group, *p < 0.01. Error bars represent the SEM.
Figure 6. Tissue-Specific and Dose-Dependent Regulation of
Protein Stability In Vivo
(A) Images of Shield-1 stabilization in the skeletal muscle of conditionally
regulated Tg-fMCDskel mice by fluorescent confocal microscopy. Animals
were injected with Shield-1 (20 mg/kg) or vehicle control.
(B) Western blot of Shield-1 dose-dependent stabilization in the skeletal
muscle of Tg-fMCDskel and control mice. Animals were injected with Shield-1
(10 mg/kg or 20mg/kg) or vehicle control.
Chemistry & Biology
Targeted Chemical-Geneticsin a more uniform expression of the transgene as assessed by
mCherry expression. Again, the administration of Shield-1 to
Tg-fMCDskel mice resulted in the induction of eYFP-MLYCD
that increased with an increasing dose of Shield-1 (Figure 6B).
These experiments show the utility of this method for modifying
protein stability in a tissue-specific and dose-dependent manner
in live mice.
DISCUSSION
Here, we have combined inducible protein stabilization with Cre-
mediated conditionally targeted mouse transgenics to produce
a broadly applicable and straightforward chemical-genetic
strategy to affect metabolism in vivo. Chemical biology and
chemical genetic techniques have been developed to probe
the function of proteins in situ in a protein-/gene-specific manner
(Bishop et al., 2000; Chen et al., 2005; Haruki et al., 2008;
Karpova et al., 2005; Liu et al., 2007; Matsuzawa et al., 2005;
McGinness et al., 2006; Robinson et al., 2010; Stankunas
et al., 2003). The use of designer small molecules that can
acutely but specifically control the function of targeted, but not
native, proteins have advantages in basic science over classical
pharmaceutical approaches. The specificity of small molecules
for their targets is inversely proportional to their popularity. In
other words, all small molecules have off-target effects that are
sometimes not appreciated decades after their introduction. In
the clinic this can be advantageous or catastrophic (Ito et al.,Chemistry & Biology 19, 32010). In basic science, these effects can be misleading in the
absence of target-specific control experiments in knockout
mice, which are rarely feasible. Designer drug-target interactions
while not useful in the clinic, can bemore exquisitely controlled in
a laboratory setting.
The transgenic approach we have designed contains several
built-in controls to allow direct visualization of stabilization,
recombination, and cellular localization simultaneously. The
addition of lox2272 sites makes this approach ideal for adding
back wild-type or mutant proteins that have been conditionally
knocked out using the more common loxP recombination sites.
Lox2272, while still being recognized by Cre recombinase, does
not efficiently recombine with LoxP, thus mitigating genomic
rearrangement. Ideally one could temporally add back a protein
into the same tissue it was deleted from and control its func-
tion via Shield-1-induced stabilization or destabilization. This
approach would be ideal for lethal null alleles or highly compen-
sated pathways. Furthermore, other orthogonal methods can be
used in conjunction with this system to achieve multiple modes
of regulation in vivo (Iwamoto et al., 2010; Nishimura et al.,
2009; Rossi and Blau, 1998).91–398, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 395
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tage of rapid development, cost effectiveness, and versatility
compared to more laborious knockin strategies. The production
of mice expressing transgenes is relatively straightforward and
accessible to most researchers. Transgenesis combined with
recombination-mediated transgene activation additionally takes
advantage of the large number of publically available tissue-
specific CRE-expressing mouse lines. Therefore, one can target
gain-of-function or gene replacement to specific cell types to
better dissect tissue-specific roles of ubiquitous genes. Making
knockin mice enables the endogenous expression of genes but
does not make it possible to discern tissue-specific effects.
Tissue-specific promoters would satisfy this as well but are not
versatile in directing transgenes to different cell types. Themeth-
odology here is beneficial in cases where one may need to
produce several groups of mice to examine, for example, the
relative role of enzymes in multiple tissues.
Low-abundance, structurally similar metabolites can be
onerous to functionally elucidate within the context of mouse
physiology, particularly when defining cause-and-effect relation-
ships. The technique described here has the potential to
intimately dissect metabolic pathways in living mice to better
understand the relationship between metabolites and metabolic
pathways and disease in distinct cell types. For example, acetyl-
CoA carboxylases alpha (ACACA) and beta (ACACB) have been
assigned differential roles in directing fatty acid metabolism, but
these roles have become unclear of late (Abu-Elheiga et al.,
2001; Harada et al., 2007; Olson et al., 2010; Savage et al.,
2006), presumably due to compensation by these closely related
enzymes. Altering specific metabolites in a cell-specific and
temporal manner will offer a more precise and nuanced under-
standing of how these enzymes and pathways contribute to
metabolic phenotypes.
SIGNIFICANCE
This mode of posttranslational control over protein stability
has the advantage of quick kinetics, dose responsiveness,
and reversibility similar to that of small-molecule pharma-
cology, with the added benefit of allele specificity. This
simple, single-vector approach to making double-condi-
tional transgenic mice provides a flexible platform to more
precisely refine protein function in vivo. Furthermore, the
reaction mechanism does not need to be known, and
large-scale chemical screening does not need to be pre-
formed. Therefore, new proteins or structurally similar
protein families can be targeted to understand their function
in mouse physiology in vivo.
EXPERIMENTAL PROCEDURES
Constructs
The FKBP12 destabilizing domain construct was fused to eYFP and a murine
malonyl-CoA decarboxylase cDNA. Several modifications were made to the
MLYCD cDNA prior to fusion with FKBP12-YFP: the mitochondrial and perox-
isomal targeting signals were removedwith the addition of flexible GSG linkers
to the N and C termini of MLYCD. Next, a viral 2A bicistronic peptide was
fused in frame linked to the red fluorescent protein mCherry to follow cellular
localization. The construct and control (lacking MLYCD) were cloned into the
retroviral vector, pLPCx (Clonetech), by standard methods.396 Chemistry & Biology 19, 391–398, March 23, 2012 ª2012 ElsevieGeneration of HEK293 Stable Cell Lines Expressing
FKBP12-YFP-MLYCD-2A-mCherry
HEK293T cells were grown in DMEM containing 10% FBS and 1% pen/strep
(Invitrogen) at 37C in a humidity-controlled chamber at 5% CO2. To produce
stable cell lines, HEK293T cells were infected with the retroviral constructs.
Stable cell lines were produced by antibiotic selection with puromycin.
Generation of Transgenic Mice
A lox2272-flanked eCFP caax STOP SV40 polyA cassette was produced by
PCR using standard methods and cloned into the pCAG vector (addgene
#13787) (Matsuda and Cepko, 2007; Reamy and Wolfgang, 2011). The
FKBP12-YFP-MLYCD-2A-mCherry transgene was cloned downstream of a
Lox 2272 CFP STOP Lox2272 cassette driven by the ubiquitous CMV-
enhanced chicken beta actin promoter (CAG). The transgenic vector was
injected into pronuclei of fertilized zygotes (B6SJLF1) at the Johns Hopkins
University School of Medicine Transgenic Mouse Core Facility. Transgenic
founders and germline transmitters were identified by testing for the expres-
sion of CFP by PCR genotyping.We crossed the resulting Tg-fMCD transgenic
mouse to a transgenic line that expresses a CREERT2 inducible by tamoxifen
(B6;129S-Tg(UBC-cre/ERT2)1Ejb/J) (Ruzankina et al., 2007) to study the
temporal regulation of MLYCD expression (referred to as Tg-fMCDERT2) or to
mice expressing Cre from a muscle-specific promoter (B6.Cg-Tg(ACTA1-
cre)79Jme/J) (Miniou et al., 1999) (referred to as Tg-fMCDskel). Cre-mediated
excision of eCFP is confirmed by genotyping PCR. All procedures were per-
formed in accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and under the approval of the Johns
Hopkins Medical School Animal Care and Use Committee.
Assay for De Novo Fatty Acid Synthesis
Stably transfected HEK293T cells expressing FY-MLYCD were plated at
a density of 4 3 105 cells in a 24 well plate (n = 6) and stimulated with
Shield-1 or vehicle at increasing concentrations for 18 hr. Cells are labeled
with 1.0 mCi of [3H] acetic acid acetate (Perkin Elmer) for an additional 2 hr.
Total lipids are extracted with chloroform/methanol and counted via liquid
scintillation.
Malonyl-CoA Decarboxylase Assay
A fluorimetric assay that measures the formation of acetyl-CoA from malonyl-
CoA, coupled with citrate synthase and malate dehydrogenase, was used to
determine MCD activity in stable HEK293 T cells expressing FY-MLYCD
(Saha et al., 2000). Cells were plated at a density of 1 3 106 cells in a 10 cm
plate, then stimulated with Shield-1 or vehicle for 24 hr. Cells were harvested
with an extraction buffer (0.1 M Tris, pH 7.4, containing 1 mM dithiothreitol
(DTT), protease, and PhosStop inhibitors cocktail (Roche)) followed by a brief
sonication. Cells were pelleted by centrifugation at 13,000 3 rpm (30 min at
4C) and supernatants were transferred to new Eppendorf tubes. Protein esti-
mation was determined using the Pierce BCA Protein Assay Kit, and 0.5 mg of
protein was used to carry out a partial purification of MCD by (NH4)2SO4. To the
lysates, 3.8 M (NH4)2SO4 was slowly added on ice with vortexing, until 60%
saturation was reached. The mixture was allowed to precipitate overnight at
4C followed by centrifugation at 13,000 3 rpm (60 min at 4C). The pellets
were resuspended in 0.1 M Tris-HCl (pH 8.0). MCD activity was measured
using a Synergy MX multimode microplate reader (BioTek Instruments, Inc.)
with excitation and emission wavelengths set to 340 and 460, respectively.
Reaction mixtures of 140 ml containing 0.1 M Tris-HCl (pH 8.0), 0.5 mM DTT,
10 mM L-malate, 0.5 mM NAD, and 17 units of malate dehydrogenase
were incubated for 7 min at 37C in a 96 well black flat-bottom assay plate.
A baseline-fluorescence measurement was followed by the addition of citrate
synthase (3.14 units), succeeded by an additional 2 min incubation. Malonyl-
CoA (0.3 mM) was added, followed by 20 ml of the (NH4)2SO4-purified sample
fraction. The incubation was allowed to continue for an additional 7 min before
a second measurement for the rate of formation of NADH was taken.
In Vivo Fatty Acid Oxidation
In vivo oxidation of 1-14C palmitic acid wasmeasured inmice by i.p. injection of
labeled palmitate (1 mCi) bound to fatty-acid-free bovine serum albumin, as
previously reported (Reamy and Wolfgang, 2011; Wolfgang et al., 2006).
Mice were individually housed in metabolic chambers and expired 14CO2r Ltd All rights reserved
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NaOH was measured by scintillation counting every 15 min for 45 min.
Western Blots
Whole tissues or stable HEK293T cells were harvested and total protein was
extracted with sonication in extraction buffer (1% (v/v) Nonidet P-40 in TBS
(50 mm Tris-HCl, pH 7.5, 150 mm NaCl) with protease and PhosSTOP phos-
phatase inhibitors cocktail (Roche). Cellular debris was pelleted at 13,000 3
rpm (30 min at 4C). Protein concentration was estimated using the Pierce
BCA Protein Assay Kit. Soluble proteins (25 or 50 mg) were separated using
Bio-Rad Tris Glycine SDS-PAGE gels (8%) or Invitrogen BisTris SDS-PAGE
gels (4%–12%). Proteins were transferred to nitrocellulose membranes,
blocked in 3% nonfat milk and detected by immunoblotting with antibodies
to FKBP12 (Thermo Scientific), dsRED (Clonetech), MLYCD (abcam), and
Heat shock Protein 8 (HSC-70) (Santa Cruz Biotechnology). HRPwas detected
using Immobilon Western Chemiluminescent substrate (Millipore Corporation,
Billerica, MA) and the FlourChem Western blot imaging system (Cell
Biosciences).
ACKNOWLEDGMENTS
We thank T.L. Wandless (Stanford University) and E. Provost (Johns Hopkins
University) for critical reagents. This work was supported in part by the
American Heart Association (SDG2310008 to M.J.W.) and NIH NINDS
(NS072241 to M.J.W.).
Received: October 5, 2011
Revised: December 15, 2011
Accepted: December 28, 2011
Published: March 22, 2012
REFERENCES
Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A., and Wakil, S.J. (2001).
Continuous fatty acid oxidation and reduced fat storage in mice lacking
acetyl-CoA carboxylase 2. Science 291, 2613–2616.
An, J., Muoio, D.M., Shiota, M., Fujimoto, Y., Cline, G.W., Shulman, G.I.,
Koves, T.R., Stevens, R., Millington, D., and Newgard, C.B. (2004). Hepatic
expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-
animal insulin resistance. Nat. Med. 10, 268–274.
Araki, K., Araki, M., and Yamamura, K. (2002). Site-directed integration of
the cre gene mediated by Cre recombinase using a combination of mutant
lox sites. Nucleic Acids Res. 30, e103.
Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G., andWandless,
T.J. (2006). A rapid, reversible, and tunablemethod to regulate protein function
in living cells using synthetic small molecules. Cell 126, 995–1004.
Banaszynski, L.A., Sellmyer, M.A., Contag, C.H., Wandless, T.J., and Thorne,
S.H. (2008). Chemical control of protein stability and function in living mice.
Nat. Med. 14, 1123–1127.
Bishop, A.C., Ubersax, J.A., Petsch, D.T., Matheos, D.P., Gray, N.S., Blethrow,
J., Shimizu, E., Tsien, J.Z., Schultz, P.G., Rose, M.D., et al. (2000). A chemical
switch for inhibitor-sensitive alleles of any protein kinase. Nature 407,
395–401.
Bonger, K.M., Chen, L.C., Liu, C.W., and Wandless, T.J. (2011). Small-mole-
cule displacement of a cryptic degron causes conditional protein degradation.
Nat. Chem. Biol. 7, 531–537.
Chen, X., Ye, H., Kuruvilla, R., Ramanan, N., Scangos, K.W., Zhang, C.,
Johnson, N.M., England, P.M., Shokat, K.M., and Ginty, D.D. (2005). A chem-
ical-genetic approach to studying neurotrophin signaling. Neuron 46, 13–21.
Harada, N., Oda, Z., Hara, Y., Fujinami, K., Okawa, M., Ohbuchi, K.,
Yonemoto, M., Ikeda, Y., Ohwaki, K., Aragane, K., et al. (2007). Hepatic de
novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol. Cell.
Biol. 27, 1881–1888.
Haruki, H., Nishikawa, J., and Laemmli, U.K. (2008). The anchor-away tech-
nique: rapid, conditional establishment of yeast mutant phenotypes. Mol.
Cell 31, 925–932.Chemistry & Biology 19, 3Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y.,
and Handa, H. (2010). Identification of a primary target of thalidomide terato-
genicity. Science 327, 1345–1350.
Iwamoto, M., Bjo¨rklund, T., Lundberg, C., Kirik, D., and Wandless, T.J. (2010).
A general chemical method to regulate protein stability in the mammalian
central nervous system. Chem. Biol. 17, 981–988.
Janse, D.M., Crosas, B., Finley, D., and Church, G.M. (2004). Localization to
the proteasome is sufficient for degradation. J. Biol. Chem. 279, 21415–21420.
Kanke, M., Nishimura, K., Kanemaki, M., Kakimoto, T., Takahashi, T.S.,
Nakagawa, T., and Masukata, H. (2011). Auxin-inducible protein depletion
system in fission yeast. BMC Cell Biol. 12, 8.
Karpova, A.Y., Tervo, D.G., Gray, N.W., and Svoboda, K. (2005). Rapid and
reversible chemical inactivation of synaptic transmission in genetically tar-
geted neurons. Neuron 48, 727–735.
Liu, K.J., Arron, J.R., Stankunas, K., Crabtree, G.R., and Longaker, M.T.
(2007). Chemical rescue of cleft palate and midline defects in conditional
GSK-3b mice. Nature 446, 79–82.
Matsuda, T., and Cepko, C.L. (2007). Controlled expression of transgenes
introduced by in vivo electroporation. Proc. Natl. Acad. Sci. USA 104, 1027–
1032.
Matsuzawa, S., Cuddy, M., Fukushima, T., and Reed, J.C. (2005). Method for
targeting protein destruction by using a ubiquitin-independent, proteasome-
mediated degradation pathway. Proc. Natl. Acad. Sci. USA 102, 14982–
14987.
Maynard-Smith, L.A., Chen, L.C., Banaszynski, L.A., Ooi, A.G., andWandless,
T.J. (2007). A directed approach for engineering conditional protein stability
using biologically silent small molecules. J. Biol. Chem. 282, 24866–24872.
McGinness, K.E., Baker, T.A., and Sauer, R.T. (2006). Engineering controllable
protein degradation. Mol. Cell 22, 701–707.
Miniou, P., Tiziano, D., Frugier, T., Roblot, N., LeMeur, M., andMelki, J. (1999).
Gene targeting restricted tomouse striatedmuscle lineage. Nucleic Acids Res.
27, e27.
Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T., and Kanemaki, M.
(2009). An auxin-based degron system for the rapid depletion of proteins in
nonplant cells. Nat. Methods 6, 917–922.
Olson, D.P., Pulinilkunnil, T., Cline, G.W., Shulman, G.I., and Lowell, B.B.
(2010). Gene knockout of Acc2 has little effect on body weight, fat mass, or
food intake. Proc. Natl. Acad. Sci. USA 107, 7598–7603.
Provost, E., Rhee, J., and Leach, S.D. (2007). Viral 2A peptides allow expres-
sion of multiple proteins from a single ORF in transgenic zebrafish embryos.
Genesis 45, 625–629.
Reamy, A.A., and Wolfgang, M.J. (2011). Carnitine palmitoyltransferase-
1c gain-of-function in the brain results in postnatal microencephaly.
J. Neurochem. 118, 388–398.
Robinson, M.S., Sahlender, D.A., and Foster, S.D. (2010). Rapid inactivation
of proteins by rapamycin-induced rerouting to mitochondria. Dev. Cell 18,
324–331.
Rossi, F.M., and Blau, H.M. (1998). Recent advances in inducible gene expres-
sion systems. Curr. Opin. Biotechnol. 9, 451–456.
Ruzankina, Y., Pinzon-Guzman, C., Asare, A., Ong, T., Pontano, L., Cotsarelis,
G., Zediak, V.P., Velez, M., Bhandoola, A., and Brown, E.J. (2007). Deletion of
the developmentally essential gene ATR in adult mice leads to age-related
phenotypes and stem cell loss. Cell Stem Cell 1, 113–126.
Saha, A.K., Schwarsin, A.J., Roduit, R., Masse, F., Kaushik, V., Tornheim, K.,
Prentki, M., and Ruderman, N.B. (2000). Activation of malonyl-CoA decarbox-
ylase in rat skeletal muscle by contraction and the AMP-activated protein
kinase activator 5-aminoimidazole-4-carboxamide-1-beta -D-ribofuranoside.
J. Biol. Chem. 275, 24279–24283.
Savage, D.B., Choi, C.S., Samuel, V.T., Liu, Z.X., Zhang, D., Wang, A., Zhang,
X.M., Cline, G.W., Yu, X.X., Geisler, J.G., et al. (2006). Reversal of diet-induced
hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide
inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116, 817–824.91–398, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 397
Chemistry & Biology
Targeted Chemical-GeneticsStankunas, K., Bayle, J.H., Gestwicki, J.E., Lin, Y.M., Wandless, T.J., and
Crabtree, G.R. (2003). Conditional protein alleles using knockin mice and
a chemical inducer of dimerization. Mol. Cell 12, 1615–1624.
Szymczak, A.L., Workman, C.J., Wang, Y., Vignali, K.M., Dilioglou, S., Vanin,
E.F., and Vignali, D.A. (2004). Correction of multi-gene deficiency in vivo using
a single ‘‘self-cleaving’’ 2A peptide-based retroviral vector. Nat. Biotechnol.
22, 589–594.
Wolfgang, M.J., and Lane, M.D. (2006). The role of hypothalamic malonyl-CoA
in energy homeostasis. J. Biol. Chem. 281, 37265–37269.398 Chemistry & Biology 19, 391–398, March 23, 2012 ª2012 ElsevieWolfgang, M.J., Kurama, T., Dai, Y., Suwa, A., Asaumi, M., Matsumoto, S.,
Cha, S.H., Shimokawa, T., and Lane, M.D. (2006). The brain-specific carnitine
palmitoyltransferase-1c regulates energy homeostasis. Proc. Natl. Acad. Sci.
USA 103, 7282–7287.
Yang, W., Rozamus, L.W., Narula, S., Rollins, C.T., Yuan, R., Andrade, L.J.,
Ram, M.K., Phillips, T.B., van Schravendijk, M.R., Dalgarno, D., et al. (2000).
Investigating protein-ligand interactions with a mutant FKBP possessing a
designed specificity pocket. J. Med. Chem. 43, 1135–1142.r Ltd All rights reserved
